TOKYO -- Japanese drugmaker Daiichi Sankyo aims to begin clinical trials of a vaccine booster candidate targeting the omicron variant of the coronavirus as soon as spring, hoping to file for authorization of the shot by April 2024.
COVID vaccines
Japan's Daiichi Sankyo to seek OK for omicron booster by April 2024
Shionogi and KM Biologics also eye homegrown shots targeting variants
Daiichi Sankyo's bivalent booster vaccine candidate contains a messenger RNA component of the original coronavirus strain and another of the BA.4 and BA.5 omicron subvariants.
Read Next
Latest on COVID vaccines
